1. [P4–384]: ANTI‐AβX‐40 ANTIBODIES EXERT NEUROPROTECTIVE EFFECT AGAINST Aβ‐OLIGOMER TOXICITY. (1st July 2017) Authors: Montañés, María; Marcos, Ivan; Canudas, Jesús; Lacosta, Ana Ma; Pesini, Pedro; Sarasa, Manuel Journal: Alzheimer's & dementia Issue: Volume 13:Supplement 7S(2017)Part 30 Page Start: P1439 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. O1‐10‐03: an Active Anti‐AB40 Vaccine (ABVAC40) Proved to be Safe and Immunogenic in the Phase i Clinical Trial. (1st July 2016) Authors: Lacosta, Ana M.; Pérez-Grijalba, Virginia; Marcos, Ivan; Sarasa, Leticia; San José, Itziar; Núñez, Laura; Boada, Mercè; Tárraga, Lluis; Ruiz, Agustin; Pesini, Pedro; Sarasa, Manuel Journal: Alzheimer's & dementia Issue: Volume 12:Supplement 7S(2016)Part 4 Page Start: P199 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Safety, tolerability and immunogenicity of an active anti‐Aβ40 vaccine (ABvac40) in patients with amnestic mild cognitive impairment (A‐MCI) or very mild alzheimer's disease (VM‐AD): A randomized, double‐blind, placebo‐controlled, phase II trial: Human/Human trials: Anti‐amyloid. (7th December 2020) Authors: Molina, Elisabet P.; Pesini, Pedro; Sarasa‐SanJose, Manuel; Marcos, Ivan; Lacosta, Ana M.; Allué, Jose A.; Fandos, Noelia; Sarasa, Manuel; Boada, Mercè Journal: Alzheimer's & dementia Issue: Volume 16(2020)Supplement 9 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗